Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD L 506 for stereotactic interstitial photodynamic therapy in newly diagnosed IDH wild-type glioblastoma
DRKS00020543Phase 2Active, not recruiting
- Sponsor
- photonamic GmbH & Co. KG
- Start
- Jan 2020
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PDL-506 in glioblastoma (GBM), sponsored by photonamic GmbH & Co. KG. Started Jan 2020; status: active, not recruiting.
02
Drugs
PDL-506
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on DRKS00020543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020543.